Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $59,508 | 2 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $59,508 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59,508 | 2 | Eli Lilly and Company ($59,508) |
All Payment Transactions
2 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $21,700.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $37,808.00 | Research |
| Study: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | Eli Lilly and Company | $37,808 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $21,700 | 1 |
About Dr. Joseph Heether, MD
Dr. Joseph Heether, MD is a Surgery healthcare provider based in Hamilton, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962510842.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Heether, MD has received a total of $59,508 in payments from pharmaceutical and medical device companies, with $59,508 received in 2024. These payments were reported across 2 transactions from 1 company. The most common payment nature is "" ($59,508).
Practice Information
- Specialty Surgery
- Location Hamilton, NJ
- Active Since 08/29/2006
- Last Updated 05/19/2020
- Taxonomy Code 208600000X
- Entity Type Individual
- NPI Number 1962510842
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Surgery Doctors in Hamilton
Gregory Ripich, Md, MD
Surgery — Payments: $137,366
Elie Goldenberg, Md, MD
Surgery — Payments: $14,260
Ryan Grote, D.o, D.O
Surgery — Payments: $11,377
Dr. Deanne Jacobs, Md, MD
Surgery — Payments: $9,538
Rajiv Shah, M.d, M.D
Surgery — Payments: $6,896
Luke Channer, M.d, M.D
Surgery — Payments: $6,248